• HBM Holdings launched a strategic partnership with BioMap to co-build AI drug developer MegaStream TechBio for global markets.
• MegaStream will combine proprietary datasets, bespoke foundation models, integrated discovery platforms to advance complex biologic pipelines.
• HBM will contribute its fully human antibody platform, target biology capabilities, clinical development experience.
• BioMap will provide AI technology, model engineering support, automated R&D capabilities to accelerate pipeline progress.
• Founders expect upfront payments, milestone payments, profit-sharing from MegaStream programs; initial pipeline to include prior joint AI projects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260615-12203685), on June 15, 2026, and is solely responsible for the information contained therein.